The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.
Site Search
Showing 11 - 20 of 307 results
News
|
Nov. 17, 2010
|
3 min read
This year, Cystic Fibrosis Advocates inspired new champions in Washington, D.C. and in state capitols across the country to take action on critical CF-related issues.
News
|
Dec. 10, 2010
|
2 min read
Revised Law Includes Designated Funding for Rare Diseases
Press Release
|
April 24, 2008
|
2 min read
News
|
Sept. 16, 2008
|
1 min read
News
|
April 11, 2008
|
1 min read
News
|
Aug. 20, 2008
|
1 min read
Historic Time in Treatment of Rare Disease as Promising Drugs Reach Phase 3 Trials
Press Release
|
Aug. 6, 2010
|
3 min read
This month, 15-year-old Molly Bonnell and her sister Emily, 13, who have cystic fibrosis, discovered how easy it is to make their voices heard in Congress -- without leaving their living room.
News
|
Aug. 20, 2010
|
2 min read
News
|
Oct. 8, 2010
|
2 min read
News
|
Aug. 11, 2014
|
2 min read